At close: June 14 at 4:00 PM EDT
After hours: June 14 at 5:31 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 6 |
| Avg. Estimate | -0.93 | -0.88 | -3.7 | -1.88 |
| Low Estimate | -1.1 | -1.04 | -4.04 | -3.25 |
| High Estimate | -0.65 | -0.56 | -2.84 | -1.15 |
| Year Ago EPS | -1.17 | -1.28 | -4.62 | -3.7 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 7 |
| Avg. Estimate | 31.71M | 38.29M | 142.59M | 260.61M |
| Low Estimate | 27M | 32M | 124M | 207M |
| High Estimate | 36.08M | 44.25M | 156.32M | 323.8M |
| Year Ago Sales | -- | 400k | 17.45M | 142.59M |
| Sales Growth (year/est) | -- | 9,472.50% | 717.30% | 82.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.08 | -1.36 | -1.36 | -1.2 |
| EPS Actual | -1.17 | -1.28 | -1.31 | -1.01 |
| Difference | -0.09 | 0.08 | 0.05 | 0.19 |
| Surprise % | -8.30% | 5.90% | 3.70% | 15.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.93 | -0.88 | -3.7 | -1.88 |
| 7 Days Ago | -0.93 | -0.88 | -3.7 | -1.88 |
| 30 Days Ago | -0.95 | -0.89 | -3.77 | -1.93 |
| 60 Days Ago | -1.11 | -1.06 | -4.36 | -2.14 |
| 90 Days Ago | -1.12 | -1.05 | -4.4 | -2.27 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TARS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 20.50% | -- | -- | 8.40% |
| Next Qtr. | 31.20% | -- | -- | 11.00% |
| Current Year | 19.90% | -- | -- | 5.10% |
| Next Year | 49.20% | -- | -- | 12.10% |
| Next 5 Years (per annum) | -20.70% | -- | -- | 11.36% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
| Maintains | Barclays: Overweight to Overweight | 5/10/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/9/2024 |
| Maintains | Jefferies: Buy to Buy | 3/6/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/29/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
Related Tickers
MLYS Mineralys Therapeutics, Inc.
12.58
-0.87%
OCS Oculis Holding AG
11.80
-0.67%
APGE Apogee Therapeutics, Inc.
41.14
-4.59%
RCKT Rocket Pharmaceuticals, Inc.
21.86
-4.37%
XNCR Xencor, Inc.
20.58
-3.43%
SLN Silence Therapeutics plc
19.30
-2.13%
KROS Keros Therapeutics, Inc.
49.36
-0.28%
VRCA Verrica Pharmaceuticals Inc.
8.12
-5.14%
IMVT Immunovant, Inc.
26.00
-2.26%
TSBX Turnstone Biologics Corp.
2.7000
-3.57%